Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02196961 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 22, 2014
Last Update Posted : September 16, 2022
|
Sponsor:
Prof. Dr. med. Dirk Schadendorf
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Prof. Dr. med. Dirk Schadendorf, University Hospital, Essen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | August 31, 2024 |
| Estimated Study Completion Date : | August 31, 2024 |